811 material Form 8-K filings that 685 companies we cover made with the SEC in April 2025, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
NETSTREIT reported first quarter 2025 results, with diluted net income of $0.02 per share, up from $0.01 a year earlier, and AFFO of $0.32 per share, up from $0.31. The company raised the low end of its 2025 AFFO per share guidance to $1.28 to $1.30 and kept its net investment guidance at $75.0 million to $125.0 million, which matters to shareholders because it changes the company's stated earnings outlook.
Total revenues were $45.9 million for the quarter, compared with $37.7 million a year earlier.
Diluted AFFO per share was $0.32, compared with $0.31 in the first quarter of 2024.
The company completed $90.7 million of investments at a 7.7% cash yield during the quarter.
The board declared a quarterly dividend of $0.21 per share, payable June 16, 2025, an annualized increase of $0.02 per share.
Crown Holdings reported first-quarter 2025 results on April 28, 2025, with diluted earnings per share of $1.65 versus $0.56 a year earlier and net sales of $2,887 million versus $2,784 million. The company raised its full-year 2025 adjusted diluted EPS guidance to $6.70 to $7.10 and reaffirmed its long-term net leverage target of 2.5x. The company also said it is monitoring the potential impact of tariffs on consumers and industrial activity.
Q1 2025 diluted EPS was $1.65 versus $0.56 in Q1 2024; adjusted diluted EPS rose 64% to $1.67.
Net sales were $2,887 million versus $2,784 million; income from operations was $365 million versus $245 million.
Full-year 2025 adjusted diluted EPS guidance raised to $6.70 to $7.10; second-quarter adjusted diluted EPS expected at $1.80 to $1.90.
Returned $233 million to shareholders in Q1, including $203 million of share repurchases.
F5 reported second-quarter fiscal 2025 revenue of $731 million, up 7% from $681 million a year earlier, and GAAP diluted earnings per share of $2.48, up from $2.00. It raised its fiscal 2025 revenue and non-GAAP earnings per share growth guidance, and separately disclosed that director Peter Klein resigned from the board effective April 25, 2025.
Q2 revenue of $731 million, up 7% from $681 million; systems revenue up 27% and software revenue flat at $158 million.
GAAP net income of $146 million, or $2.48 per diluted share, versus $119 million, or $2.00 per diluted share, a year earlier.
Fiscal 2025 revenue growth guidance raised to 6.5% to 7.5% from 6% to 7%; non-GAAP EPS growth guidance raised to 8% to 10% from 6.5% to 8.5%.
Director Peter Klein resigned effective April 25, 2025; Julie Gonzalez was named Audit Committee chair and the board was reduced from twelve to eleven members.
Cadence reported first quarter 2025 revenue of $1.242 billion, up from $1.009 billion a year earlier, and non-GAAP diluted EPS of $1.57, up from $1.17. The company raised its full-year 2025 revenue and non-GAAP EPS outlook, and GAAP net income rose to $273.6 million from $247.6 million.
Q1 revenue $1.242 billion vs $1.009 billion in Q1 2024; GAAP diluted EPS $1.00 vs $0.91
FY 2025 revenue outlook raised to $5.15 billion to $5.23 billion from $5.14 billion to $5.22 billion; non-GAAP EPS outlook raised to $6.73 to $6.83 from $6.65 to $6.75
Q2 2025 revenue outlook of $1.25 billion to $1.27 billion; non-GAAP EPS of $1.55 to $1.61
Repurchased $350 million of common stock in Q1 2025
Revvity reported first-quarter 2025 revenue of $665 million, up from $650 million a year earlier, and GAAP EPS of $0.35 versus $0.21. Adjusted EPS from continuing operations was $1.01 versus $0.98. The company raised its full-year 2025 revenue guidance to $2.83-$2.87 billion, citing currency changes, and reaffirmed its organic growth and adjusted EPS guidance.
Q1 2025 revenue of $665 million, up 2% reported and 4% organic, versus $650 million a year earlier.
GAAP EPS of $0.35 versus $0.21; adjusted EPS from continuing operations of $1.01 versus $0.98.
Full-year 2025 revenue guidance raised to $2.83-$2.87 billion; organic growth guidance of 3-5% and adjusted EPS guidance of $4.90-$5.00 reaffirmed.
Diagnostics adjusted operating margin fell to 22.8% from 24.3%, while Life Sciences margin rose to 31.1% from 30.0%.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.